

Corresponding author(s):	Sean Brady
Last updated by author(s):	Jul 18, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

_					
C1	1	11	ist	т.	$\sim c$
_) I			ואו	- 11	١,

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\times	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for high gaists contains articles on many of the points above

Software and code

Policy information about availability of computer code

Data collection

Amplicon sequence data was collected using the MiSeq Control Software (2.6.2.1) on a MiSeq sequencing instrument (Illumina). Untargeted sequencing was collected using the Illumina HiSeq software suite (HCS 2.2.68) on a HiSeq 2500 instrument.

Data analysis

Downstream analysis scripts are publicly available in https://github.com/brady-lab-rockefeller/conkat_seq and https://github.com/brady-lab-roc lab-rockefeller/BGCs_in_rare_metagenomic_DNA. Analysis was performed using Python 2.7.15 (Anaconda, Inc.) with the following module dependencies: numpy (1.14.3), pandas (0.23.0), networkx (2.1), BioPython (1.68), scipy (1.1.0) and statsmodels (0.9.0). Amplicon sequences were demultiplexed using a Python script avaialbe at https://github.com/brady-lab-rockefeller/paired-end-debarcoder. Primer removal, amplicon length trimming and clustering were performed using VSEARCH (version 2.9.1). Alignment of reads to reference sequences was performed using BBmap (version 38.22), SAMtools (version 1.9), and bedtools (version 2.27.1). Biosynthetic domains were compared to each others and to reference sequences using blastp (version 2.6.0+). Statistical analysis of amplicon co-occurrences was performed using one-sided Fisher's exact test as implemented in the "fisher exact" function in scipy stats module. P-values were adjusted to control false-discovery rate using a 2-stage Benjamini-Krieger-Yekutieli procedure as implemented in the "multipletests" function in statsmodels.stats module. Detection and annotation of biosynthetic gene cluster was performed using antiSMASH (version 4.1). Similarity metric scores between biosynthetic gene clusters was calculated using BiG-SCAPE (version 20181005). Domain networks were visualized with Cytoscape (version 3.7.1). NMR data was analyzed with MNOVA.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

Clinical data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All sequences of metagenomic inserts harboring BGCs reported in this work are available from genbank (Accession number pending) and from https://github.com/brady-lab-rockefeller/BGCs_in_rare_metagenomic_DNA. Demultiplexed reads of the AD domains and domain networks from the Arizona library are available from https://github.com/brady-lab-rockefeller/BGCs_in_rare_metagenomic_DNA. The remaining data that support the findings of this study are available from the corresponding author upon reasonable request.

Field-spe	ecific reporting			
Please select the o	one below that is the best fit for yo	our research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences	Behavioural & socia	al sciences Ecological, evolutionary & environmental sciences		
For a reference copy of	the document with all sections, see <u>nature</u>	.com/documents/nr-reporting-summary-flat.pdf		
Life scier	nces study desi	gn		
All studies must di	sclose on these points even wher	the disclosure is negative.		
Sample size	No sample-size calculation was performed			
Data exclusions	Sequencing data of ketosynthase domains from one of the six 384 plates of the Arizona library were excluded due to very low sequencing coverage. Consequently only 1920 subpools out of 2304 were processed for Arizona ketosynthase domains co-occurrence analysis.			
Replication	n/a			
Randomization	n/a			
Blinding	n/a			
We require informat	ion from authors about some types o	naterials, systems and methods f materials, experimental systems and methods used in many studies. Here, indicate whether each material, e not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & experimental systems		Methods		
n/a Involved in the study		n/a Involved in the study		
Antibodies		ChIP-seq		
Eukaryotic cell lines		Flow cytometry		
Palaeontology		MRI-based neuroimaging		
	nd other organisms			
Human re	Human research participants			